Search publications

Publications

  • Zarei M, Pizarro J, Barroso E, Palomer FX and Vazquez M.

    Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis.

    TRENDS PHARMACOL SCI . 41(3): 199-208.

    [doi:10.1016/j.tips.2019.12.005]

  • Palomer FX, Román-Azcona MS, Pizarro J, Planavila A, Villarroya F, Valenzuela-Alcaraz BI, Crispi F, Sepúlveda-Martínez Á, Miguel-Escalada I, Ferrer J, Nistal JF, García R, Davidson MM, Barroso E and Vazquez M.

    SIRT3-mediated inhibition of FOS through histone H3 deacetylation prevents cardiac fibrosis and inflammation.

    signal transduction and targeted therapy . 5(1): 14-14.

    [doi:10.1038/s41392-020-0114-1]

  • Zarei M, Pujol E, Quesada T, Villarroya F, Barroso E, Vázquez S, Pizarro J, Palomer FX and Vazquez M.

    Oral administration of a new HRI activator as a new strategy to improve high-fat-diet-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21.

    BRITISH JOURNAL OF PHARMACOLOGY . 176(13): 2292-2305. Number of citations: 4

    [doi:10.1111/bph.14678]

  • Botteri G, Salvadó L, Gumà A, Hamilton DL, Meakin PJ, Montagut G, Ashford MLJ, Ceperuelo-Mallafré V, Fernández-Veledo S, Vendrell J, Calderón-Dominguez M, Serra D, Herrero L, Pizarro J, Barroso E, Palomer FX and Vazquez M.

    Corrigendum to "The BACE1 product sAPP induces ER stress and inflammation and impairs insulin signaling" [Metab Clin Exp 85 (2018) 59-75].

    METABOLISM-CLINICAL AND EXPERIMENTAL . 96: 101-102.

    [doi:10.1016/j.metabol.2019.04.009]

  • Márquez A, Aymerich J, Dei M, Rodríguez-Rodríguez R, Vazquez M, Pizarro J, Giménez-Gómez P, Merlos Á, Terés L, Serra-Graells F, Jiménez-Jorquera C, Domínguez C and Muñoz-Berbel X.

    Reconfigurable multiplexed point of Care System for monitoring type 1 diabetes patients.

    BIOSENSORS & BIOELECTRONICS . 136: 38-46. Number of citations: 2

    [doi:10.1016/j.bios.2019.04.015]

  • Botteri G, Salvadó L, Gumà A, Lee Hamilton D, Meakin PJ, Montagut G, Ashford MLJ, Ceperuelo-Mallafré V, Fernández-Veledo S, Vendrell J, Calderón-Dominguez M, Serra D, Herrero L, Pizarro J, Barroso E, Palomer FX and Vazquez M.

    The BACE1 product sAPPß induces ER stress and inflammation and impairs insulin signaling.

    METABOLISM-CLINICAL AND EXPERIMENTAL . 85: 59-75. Number of citations: 11

    [doi:10.1016/j.metabol.2018.03.005]

  • Palomer FX, Pizarro J and Vazquez M.

    Emerging Actors in Diabetic Cardiomyopathy: Heartbreaker Biomarkers or Therapeutic Targets?

    TRENDS PHARMACOL SCI . 39(5): 452-467. Number of citations: 17

    [doi:10.1016/j.tips.2018.02.010]

  • Palomer FX, Barroso E, Pizarro J, Pena L, Botteri G, Zarei M, Aguilar D, Montori M and Vazquez M.

    PPARß/d: A Key Therapeutic Target in Metabolic Disorders.

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 19(3): 913. Number of citations: 31

    [doi:10.3390/ijms19030913]

  • Palomer FX, Pizarro J, Barroso E and Vazquez M.

    Palmitic and Oleic Acid: The Yin and Yang of Fatty Acids in Type 2 Diabetes Mellitus.

    TRENDS IN ENDOCRINOLOGY AND METABOLISM . 29(3): 178-190. Number of citations: 93

    [doi:10.1016/j.tem.2017.11.009]

  • Botteri G, Montori M, Gumà A, Pizarro J, Cedó L, Escolà-Gil JC, Li D, Barroso E, Palomer FX, Kohan AB and Vazquez M.

    VLDL and apolipoprotein CIII induce ER stress and inflammation and attenuate insulin signalling via Toll-like receptor 2 in mouse skeletal muscle cells

    Diabetologia . 60(11): 2262-2273. Number of citations: 8

    [doi:10.1007/s00125-017-4401-5]